Anti-hormonal Maintenance Treatment With the CDK4/6 Inhibitor Ribociclib After 1st Line Chemotherapy in Hormone Receptor Positive / HER2 Negative Metastatic Breast Cancer: A Phase II Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Sep 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ribociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms AMICA

06 Jul 2023 Status changed from discontinued to completed.
10 Dec 2022 The study was amended after inclusion of 37 patients due to slow accrual.
10 Dec 2022 Status changed to discontinued, according to Results presented at the 45th Annual San Antonio Breast Cancer Symposium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com